Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 9INDUSTRY 3NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25Leukemia, Myeloid, Chronic-Phase 14Leukemia 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Recurrence 4Breast Neoplasms 4Blast Crisis 4Prostatic Neoplasms 3Neoplasms 3Bronchiolitis Obliterans Syndrome 3Neoplasm Metastasis 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Advanced Breast Cancer 2Philadelphia Chromosome 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Indications Cancer 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Advanced Cancer 1

Interventions

Prednisone 103enzalutamide 76Docetaxel 72Abiraterone Acetate 68Leuprolide 47acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 45abiraterone 39apalutamide 29Prednisolone 27bicalutamide 26Zoledronic Acid 24radium Ra 223 dichloride 22pembrolizumab 22darolutamide 22Goserelin 22Triptorelin Pamoate 17cabazitaxel 16Androgen Antagonists 15sipuleucel-T 13luprolide acetate gel depot 12Injections 12Dexamethasone 12olaparib 11gallium 68 PSMA-11 10Mitoxantrone 10Pluvicto 9Ipilimumab 9Dutasteride 9Cyclophosphamide 9relugolix 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Prostatic Neoplasms × Dasatinib × Clear all
NCT00744497 2016-10-17

READY

Bristol-Myers Squibb

Phase 3 Completed
1,930 enrolled 23 charts
Genitourinary

Prostatic Neoplasms

NCT00439270 2014-03-28

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

Bristol-Myers Squibb

Phase 1/2 Completed
49 enrolled 25 charts
Genitourinary

Prostatic Neoplasms

NCT00385580 2013-04-30

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

Bristol-Myers Squibb

Phase 2 Completed
94 enrolled 50 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡